耳鼻咽喉科手术患者围手术期使用去氨加压素的系统评价
该系统评价检索PubMed、MEDLINE和EmBase,纳入19项研究共440例患者,评估去氨加压素在耳鼻咽喉科手术中的用途、疗效和不良反应。去氨加压素可有效预防高危患者出血并在需要时促进术野干燥,症状性使用时成功率为100%;不良反应包括低钠血症(12.3%)、恶心(2.0%)、呕吐(0.9%)和癫痫发作(0.2%)。证据等级为腺样体扁桃体切除术、鼻中隔成形术和鼻甲手术B级,鼻成形术C级。
要点
- 去氨加压素可预防高危患者出血并促进术野干燥,症状性使用成功率100%。
- 不良反应包括低钠血症(12.3%)、恶心(2.0%)、呕吐(0.9%)和癫痫发作(0.2%)。
- 证据等级:腺样体扁桃体切除术、鼻中隔成形术和鼻甲手术为B级,鼻成形术为C级。
核心结论
- 当前文献支持在耳鼻咽喉科手术中将去氨加压素用作围手术期预防性药物和术后出血的症状性干预措施,两者均有效且不良事件轻微。
- 需要进一步精心设计的随机试验才能最终制定去氨加压素在耳鼻咽喉科使用的指南。
研究设计与样本
- 系统评价,检索PubMed、MEDLINE和EmBase中关于去氨加压素在耳鼻咽喉科使用的文章。
- 使用非随机研究方法学指数标准和Cochrane偏倚工具评估研究质量,收集患者人口学、去氨加压素剂量和给药途径以及出血和不良事件等结局。
- 共纳入19项研究,涵盖440例患者;16项研究讨论预防性使用,3项讨论术后使用。
主要发现
- 去氨加压素有效预防高危患者出血,并在需要时成功促进术野干燥。
- 去氨加压素症状性使用时成功率为100%。
- 5项研究描述了不良反应,包括低钠血症(12.3%)、恶心(2.0%)、呕吐(0.9%)和癫痫发作(0.2%)。
- 去氨加压素使用的总体证据等级为:腺样体扁桃体切除术、鼻中隔成形术和鼻甲手术B级,鼻成形术C级。
关键数值与推荐
- 证据等级:腺样体扁桃体切除术、鼻中隔成形术和鼻甲手术为B级;鼻成形术为C级。
- 症状性使用去氨加压素成功率为100%。
- 不良反应发生率:低钠血症12.3%、恶心2.0%、呕吐0.9%、癫痫发作0.2%。
临床怎么用
- 当前文献支持在耳鼻咽喉科手术中将去氨加压素用作围手术期预防性药物和术后出血的症状性干预措施,两者均有效且不良事件轻微。
- 需要进一步精心设计的随机试验才能最终制定去氨加压素在耳鼻咽喉科使用的指南。
局限性
- 需要进一步精心设计的随机试验才能最终制定去氨加压素在耳鼻咽喉科使用的指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Desmopressin (DDAVP) is a hemostatic agent used to manage bleeding in patients with hemostatic disorders, and there is a lack of published data to guide its use during otolaryngology procedures. The objective of this study was to conduct an evidence-based systematic review of the reported uses, efficacy, and adverse effects of DDAVP in the otolaryngology surgical setting. DATA SOURCES: PubMed, MEDLINE, and EmBase were searched for articles on the use of DDAVP in otolaryngology. REVIEW METHODS: The Methodological Index for Non-Randomized Studies criteria and Cochrane bias tool were used to assess study quality. Patient demographics, DDAVP dosing and route, and outcomes such as bleeding and adverse events were collected. A summary of evidence table was created specifying levels of evidence, benefits, and harm. RESULTS: Nineteen studies encompassing 440 patients were included. Sixteen studies discussed DDAVP for prophylaxis, and 3 discussed postoperative use. DDAVP effectively prevented bleeding in high-risk patients and successfully facilitated a dry surgical field when necessary. DDAVP had a 100% success rate when used symptomatically. Five studies described adverse effects, including hyponatremia (12.3%), nausea (2.0%), emesis (0.9%), and seizure (0.2%). The aggregate level of evidence for its use was Level B for adenotonsillectomy, septoplasty, and turbinate procedures and Level C for rhinoplasty. CONCLUSION: Current literature supports the use of DDAVP in otolaryngology surgical procedures as both a perioperative prophylactic agent and a postoperative symptomatic intervention for bleeding. Both modalities are effective with minimal adverse events. Further well-designed randomized trials are necessary to conclusively formulate guidelines for DDAVP use in otolaryngology.
引用
- Barinsky GL, Buziashvili D, Svider PF, et al. Perioperative Desmopressin for Patients Undergoing Otolaryngologic Procedures: A Systematic Review. Otolaryngol Head Neck Surg. 2019. PMID: 30857487. doi:10.1177/0194599819831288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。